Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

Table 1 Characteristics of patients

	Group I	Group II	Group III	Group IV
n	37	31	21	24
Age (median, IQR)	43 (31–59)	52 (42–56)	65 (37–72)	60 (50–72)
Gender (male/female)	19/18	13/18	11/10	14/10
IMID* (RA/SA/CD)	13/12/12	16/13/2	0	0
TNF antagonists*
RA (Ifx/Ada/Eta)	11 (0/1/10)	12 (3/2/7)	0	0
SA (Ifx/Ada/Eta)	9 (2/1/6)	13 (8/1/4)
CD (Ifx/Ada/Eta)	11 (11/0/0)	0 (0/0/0)
Previous anti-TB treatment	0	2	0	20
Associated immunosuppressors (MTX/AZA/CT)	17/6/18	14/1/11	0	0
TST (≥10 mm)	0/37	31/31	0/21	24/24

*A few patients were studied at inclusion but not at week 14. Ada, adalimumab; AZA, azathioprine; CD, Crohn's disease; CT, corticosteroids (≤10 mg/day); Eta, etanercept; Ifx, infliximab; IMID, immune-mediated inflammatory disease; IQR, interquartile range; MTX, methotrexate; RA, rheumatoid arthritis; SA, spondylarthropathy; TB, tuberculosis; TNF, tumour necrosis factor; TST, tuberculin skin test.

ISSN: 1478-6362